Free Trial

Addex Therapeutics (ADXN) Competitors

Addex Therapeutics logo
$8.27 +0.00 (+0.05%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ADXN vs. KZR, CLNN, OKUR, RNTX, FGEN, BDRX, ESLA, MIRA, DYAI, and SCYX

Should you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Kezar Life Sciences (KZR), Clene (CLNN), OnKure Therapeutics (OKUR), Rein Therapeutics (RNTX), FibroGen (FGEN), Biodexa Pharmaceuticals (BDRX), Estrella Immunopharma (ESLA), MIRA Pharmaceuticals (MIRA), Dyadic International (DYAI), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical products" industry.

Addex Therapeutics vs. Its Competitors

Kezar Life Sciences (NASDAQ:KZR) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

In the previous week, Kezar Life Sciences had 1 more articles in the media than Addex Therapeutics. MarketBeat recorded 2 mentions for Kezar Life Sciences and 1 mentions for Addex Therapeutics. Kezar Life Sciences' average media sentiment score of 0.93 equaled Addex Therapeutics'average media sentiment score.

Company Overall Sentiment
Kezar Life Sciences Positive
Addex Therapeutics Positive

67.9% of Kezar Life Sciences shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 10.4% of Kezar Life Sciences shares are owned by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Kezar Life Sciences presently has a consensus target price of $39.50, suggesting a potential upside of 816.47%. Addex Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 263.37%. Given Kezar Life Sciences' higher possible upside, equities research analysts clearly believe Kezar Life Sciences is more favorable than Addex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kezar Life Sciences
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Addex Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Addex Therapeutics has a net margin of 3,584.49% compared to Kezar Life Sciences' net margin of 0.00%. Addex Therapeutics' return on equity of -54.27% beat Kezar Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Kezar Life SciencesN/A -61.15% -50.27%
Addex Therapeutics 3,584.49%-54.27%-49.15%

Kezar Life Sciences has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.

Addex Therapeutics has lower revenue, but higher earnings than Kezar Life Sciences. Addex Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kezar Life Sciences$7M4.50-$83.74M-$10.82-0.40
Addex Therapeutics$170.62K51.29$8.02M-$0.34-24.28

Summary

Addex Therapeutics beats Kezar Life Sciences on 9 of the 14 factors compared between the two stocks.

Get Addex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADXN vs. The Competition

MetricAddex TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.77M$2.50B$5.70B$9.51B
Dividend YieldN/A1.75%4.69%4.01%
P/E Ratio-24.289.0528.0720.05
Price / Sales51.29757.64448.5799.42
Price / CashN/A165.2136.2258.56
Price / Book0.805.168.665.87
Net Income$8.02M$30.99M$3.25B$258.55M
7 Day Performance9.50%7.74%4.20%2.23%
1 Month Performance-5.27%16.18%10.82%12.76%
1 Year Performance3.20%-1.03%34.70%19.36%

Addex Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADXN
Addex Therapeutics
2.1843 of 5 stars
$8.26
-0.2%
$30.00
+263.4%
+3.4%$8.77M$170.62K-24.2830Gap Up
KZR
Kezar Life Sciences
4.1969 of 5 stars
$4.30
-1.1%
$39.50
+818.6%
-32.4%$31.78M$7M-0.4060
CLNN
Clene
3.4299 of 5 stars
$3.87
+1.3%
$40.00
+933.6%
-19.2%$31.58M$340K-0.96100
OKUR
OnKure Therapeutics
3.4043 of 5 stars
$2.32
-0.4%
$32.33
+1,293.7%
N/A$31.48MN/A-0.44N/APositive News
RNTX
Rein Therapeutics
N/A$1.44
+1.4%
N/AN/A$31.46MN/A-0.509
FGEN
FibroGen
4.5894 of 5 stars
$7.56
-1.2%
$250.00
+3,206.9%
-76.9%$30.92M$7.00M-3.02570Positive News
BDRX
Biodexa Pharmaceuticals
0.2905 of 5 stars
$0.85
+0.7%
N/AN/A$30.86M$470K0.0020Positive News
ESLA
Estrella Immunopharma
3.3035 of 5 stars
$0.84
-1.5%
$16.00
+1,804.8%
-40.7%$30.86MN/A-3.23N/AGap Down
MIRA
MIRA Pharmaceuticals
2.5791 of 5 stars
$1.68
-6.7%
$14.00
+733.3%
-26.3%$30.45MN/A-3.292
DYAI
Dyadic International
3.304 of 5 stars
$1.00
+2.7%
$6.00
+500.0%
-18.8%$29.30M$3.49M-5.007Positive News
SCYX
SCYNEXIS
0.9025 of 5 stars
$0.71
-1.9%
N/A-63.5%$28.29M$3.75M-1.2760Positive News

Related Companies and Tools


This page (NASDAQ:ADXN) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners